Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024
Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.
The total market for recombinant hemophilia treatment in the 5EU is expected to grow from approximately $2.08 billion in 2014 to $2.36 billion in 2024. This growth will be driven by increasing rates of recombinant factor replacement therapies across the 5EU countries; in Italy and Spain in particular, where the current rate of prophylactic treatment is relatively low, an increasing proportion of adult patients are getting prophylactic treatments. GlobalData expects moderate and high rates of adoption of the long-acting rFVIII and rFIX therapies, respectively, over the forecast period. However, GlobalData’s primary research indicates that the high annual cost of therapy is of great concern among physicians and regulators in Europe and therefore the opportunities for premium pricing for new therapies will be limited during the forecast period.
Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in 5EU from 2014-2024.
Analysis of the impact of key events as well the drivers and restraints affecting 5EU Hemophilia A and B market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2014-2024 in 5EU.